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23; HAS: 28; G-BA: 11; IQWiG: 11) covering 31 oncology drugs were reviewed. Thirteen 
(42%) of these drugs had ≥ 1 PRO claims in their European label; corresponding HTA 
submissions also included PROs. Manufacturers presented PROs in 67.1% (57/85) of 
HTA submissions (BC: 72.7%; NSCLC: 100%; PaC: 0%; PC: 77.3%; leukemias: 43.5%). 
PROs were also presented in the HTA submissions of 8 drugs with no EMA PRO data. 
In HTA submissions, PROs assessing QoL (51/57, 89.4%) and pain (18/57, 31.6%) were 
the most common. Statistical significance was observed in 59.6% of the 52 submis-
sions with available results. In the final HTA decision, PROs were mentioned for 
43.9% of submissions, not mentioned in 35.1% and were not reviewed by the HTA 
body in 21.0% of submissions due mainly to methodological issues. ConClusions: 
Demonstrating a statistically significant improvement in PROs does not increase 
the chance of a positive HTA recommendation (65.5% vs 74.1% for submissions 
without PROs). The value that PRO claims in oncology have to payers needs to be 
further clarified.
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objeCtives: Lung cancer is the leading cause of cancer-related mortality world-
wide. Patients experience symptoms throughout the course of their disease which 
detrimentally affect their health-related quality of life (HRQOL). The assessment 
and monitoring of changes in NSCLC symptoms is increasingly important in clini-
cal trials when making treatment comparisons between therapies. The objective 
was to develop a brief assessment of core symptoms appropriate for use in clini-
cal trials. Methods: This non-interventional, cross-sectional qualitative study 
consisted of conducting individual interviews with NSCLC patients. Patients aged 
≥ 18 years with stage IIB-IV NSCLC participated in individual interviews to provide 
descriptions of NSCLC symptoms, including severity, frequency and change over 
time. Results: 17 treatment-naïve patients (mean age= 68yrs) were recruited for 
concept elicitation interviews. The most common spontaneously reported symp-
toms of NSCLC were cough (58.8%), shortness of breath (47.1%), chest pain (47.1%) 
and fatigue (29.4%). These symptoms were included in the initial 12-item version 
of the Symptoms In Lung Cancer (SILC) scale. An additional 10 post-treatment 
patients (mean age= 63yrs) participated in cognitive interviews to ensure that the 
items were correctly interpreted, relevant, and disease-related (i.e., not treatment-
related). They overall found the SILC easy to complete and interpreted most of 
the items as intended. Items related to fatigue were removed as post-treatment 
patients found these concepts difficult to attribute to their disease, and were 
reported by less than a third of treatment-naïve patients. The final 9-item SILC 
uses a 5-point verbal response scale (higher scores indicating greater severity/
frequency), a 7-day recall period, and assesses 3 core symptom concepts: chest 
pain (severity and frequency), cough (severity and frequency), dyspnea (while 
lying down/sitting, standing, walking, carrying a light load and when walking up 
an incline). ConClusions: SILC is an easy-to-use and concise tool to assess the 
core symptoms of disease in NSCLC patients.
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objeCtives: The risk of nocosomial infections plays important role especially for 
patients with severe sicknesses and lenghty hospital stays. To better understand 
associated risk factors, real world evidence data from primary care patients was 
analyzed. Methods: 5,817 primary care patients from 982 general practices (GP) 
with first diagnosis of intra- or postoperative complications (“IPC”) (in digestive sys-
tem (ICD 10: K91) or circulatory system (ICD 10: I97)) were identified during the index 
period 04/2010-03/2015 from the Disease Analyzer database, Germany). Furthermore, 
5,817 controls were included after individual matching (1:1) to study cases on age, 
gender, type of health insurance (private or statutory) and the physician. Results: 
Study patients in both groups were 64 yrs old on average, 3% were female. The share 
of patients with cancer diagnosis was higher in the case than in the control group 
(21.5% versus 5.8%, p< 0.001), e.g. significant differences were identified in shares of 
breast cancer (7.3% versus 1.0%, p< 0.001) or cancer of digestive organs (8.4% versus 
0.9%, p< 0.001). There were no significant differences in the shares of prostate, skin 
and respiratory organ cancer. In multivariate regression models, newly diagnosed 
IPC were significantly associated with cancer (Odds ratio, OR, 95%CI: 4.58, 4.03-5.20), 
as well as with breast cancer (8.51, 6.41-11.29) and cancer of digestive organs (10.49, 
7.87-14.00) among others. ConClusions: This study suggests that cancer diagnosis 
might be a risk factor for the development of ICP. More specifically, certain tumors, 
like breast cancer or cancer of digestive organs are more likely to be associated with 
ICP than others (e.g. prostate or skin cancer). Potential reasons for this observa-
tions, e.g. differences in therapy duration or frequency and complexity of surgical 
procedures, have to be investigated.
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objeCtives: Symptom burden is critical for assessing therapeutic efficacy in 
myelofibrosis, characterized by splenomegaly, abdominal and constitutional 
they were completing it at their outpatient clinic. Such data collection must be tied 
to a transparent clinical purpose that patients see as an integral part of their health 
care. Other avenues for collecting outpatient drug toxicities outcomes should be 
investigated.
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objeCtives: Explore the use of social media for health data collection in effective-
ness research in oncology. Methods: We conducted a systematic review of scien-
tific literature to assess health data collected via social media. Literature published 
in PubMed between January 2010 and April 2015 was included. Three reviewers 
screened studies for eligibility and extracted data. Based on included articles an 
explanatory and qualitative analysis was performed. Results: Initially the search 
strategy identified 580 articles. Study inclusion criteria were met by 12 articles 
based on title and abstract, and by 4 articles based on the full paper. Two additional 
articles were included after evaluating the reference lists of included hits. Of the 6 
included articles, four focused on identifying side effects to cancer treatments by 
using patient forum websites, one assessed the feasibility of disseminating a qual-
ity of life survey via a Facebook support group, and one focused on methodological 
considerations in analyzing data from Twitter. Several benefits of health data gener-
ated via social media were discussed, such as the ability to provide additional infor-
mation on (unlabelled) side effects, the recruitment of a small sample of patients 
spread over a relatively wide geographic area, and the possibility to capture patient 
perspectives that tend to be more difficult to measure in clinical trials. Limitations 
of using social media to generate health data included validating authenticity of 
posts and users, duplicate and multiple posts, the volume of data available, selec-
tion bias (e.g. sicker or older patients may not be represented on social media) and 
incompleteness of data on patient characteristics. ConClusions: Limited litera-
ture is available on the actual use of health data from social media in effectiveness 
research in oncology. However, the potential of health data collected via social media 
is of increasing interest in the scientific community and should be further explored.
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objeCtives: To understand disease-related symptoms experienced by high-risk 
non-muscle invasive bladder cancer (NMIBC) patients, selected treatment patterns, 
patient satisfaction with their treatment and concern regarding future potential 
treatments. Methods: Ten interviews were conducted with patients recruited at 
two urology clinics in the United States; patients were recruited by clinic staff. 
Patients were eligible to participate if they met one of the following three criteria: 
1) were Bacillus Calmette–Guérin (BCG)-naïve treated with transurethral resection 
of bladder tumor (TURBT) ± intravesical chemotherapy; 2) had current or previous 
BCG treatment but were refractory or resistant to treatment; or 3) were BCG refrac-
tory or relapsing and whose next treatment option would be cystectomy but were 
prior to cystectomy. Results: Participants were demographically representative 
of the patient population that seeks treatment for NMIBC. Nearly all interview par-
ticipants reported visible hematuria as the symptom which led to their diagnosis. 
Other disease-specific symptoms were not frequently reported. All participants had 
received one or more NMIBC drugs (i.e., BCG, mitomycin, valrubicin), a procedure 
(i.e., TURBT, cystoscopy), or both. All participants reported transient medication 
side effects (e.g., painful urination, urgency, frequency) and/or catheter or stent 
adverse events (e.g., painful or burning urination, passing blood clots) following their 
procedure or surgery. Despite these findings, almost all participants were satisfied 
with their treatment. All patients were concerned about the possibility of cystec-
tomy, should their disease progress, and were highly motivated to avoid this treat-
ment. ConClusions: Patients reported disease and treatment-related symptoms; 
however, they were not severe enough to impact the patient’s willingness to undergo 
intravesical therapy or diagnostic procedures. Further research is needed to better 
characterize the impact of timing and duration of treatment-related symptoms, as 
well as patient and caregiver perspective on additional bladder cancer therapies, 
especially when bladder sparing may be warranted.
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objeCtives: In parallel with increasing requests for PROs to be assessed in oncology 
trials, the European Medicine Agency (EMA) in 2014 published a reflection paper 
outlining their recommendations. The value PRO claims have to HTA Agencies is less 
clear. Our objective was to assess whether HTA agencies placed a similar valuation 
on PROs as the EMA. Methods: Our focus was HTA agencies in key 3 European 
countries: Germany, the UK and France Cancer types were selected where they had 
a high number of HTA assessments: breast cancer (BC), non-small cell lung cancer 
(NSCLC), pancreatic cancer (PaC); prostate cancer (PC) and leukaemias. Relevant 
HTA appraisals since January 2013 were identified using Quintiles’ proprietary 
HTA Accelerator database. The drugs evaluated were compared to their respective 
European labels. Results: Overall, 85 HTA submissions (AWMSG: 5; NICE: 7; SMC: 
